,address1,city,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,42 Hayarkon Street,Yavne,8122745,Israel,972 7 797 14100,972 7 797 14111,https://www.mediwound.com,Biotechnology,Healthcare,"MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.",83,"{'maxAge': 1, 'name': 'Mr. Ofer  Gonen B.Sc.', 'age': 49, 'title': 'Chief Exec. Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 485000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,9.0,9.05,8.92,9.5,9.0,9.05,8.92,9.5,0.0,1.095781,-4.7395835,40748,40748,15720,42330,42330,8.03,9.55,800,800,86219408,7.1,14.58,3.3170242,9.0635,10.88194,0.0,0.0,USD,6122425,-0.55526,3789147,9474660,41079,46061,1690761600,1693440000,0.0043,0.24237,0.29609,3.88,0.0052,4.816,1.889535,1672444800,1703980800,1688083200,-14433000,-2.5,-1.92,-0.06,0.236,-0.75,NGM,EQUITY,MDWD,MDWD,MediWound Ltd.,MediWound Ltd.,1395322200,America/New_York,EDT,-14400000,9.1,36.0,23.0,27.25,25.0,1.7,buy,4,51122000,7.049,-8166000,677000,6.612,6.987,25993000,1.938,3.626,-0.12971,-0.88291,13165000,-7635750,-7165000,0.022,0.48301,-0.31416,-0.34120998,USD,
1,42 Hayarkon Street,Yavne,8122745,Israel,972 7 797 14100,972 7 797 14111,https://www.mediwound.com,Biotechnology,Healthcare,"MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.",83,"{'maxAge': 1, 'name': 'Dr. Lior  Rosenberg M.D.', 'age': 76, 'title': 'Co-Founder', 'yearBorn': 1946, 'fiscalYear': 2022, 'totalPay': 727000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,9.0,9.05,8.92,9.5,9.0,9.05,8.92,9.5,0.0,1.095781,-4.7395835,40748,40748,15720,42330,42330,8.03,9.55,800,800,86219408,7.1,14.58,3.3170242,9.0635,10.88194,0.0,0.0,USD,6122425,-0.55526,3789147,9474660,41079,46061,1690761600,1693440000,0.0043,0.24237,0.29609,3.88,0.0052,4.816,1.889535,1672444800,1703980800,1688083200,-14433000,-2.5,-1.92,-0.06,0.236,-0.75,NGM,EQUITY,MDWD,MDWD,MediWound Ltd.,MediWound Ltd.,1395322200,America/New_York,EDT,-14400000,9.1,36.0,23.0,27.25,25.0,1.7,buy,4,51122000,7.049,-8166000,677000,6.612,6.987,25993000,1.938,3.626,-0.12971,-0.88291,13165000,-7635750,-7165000,0.022,0.48301,-0.31416,-0.34120998,USD,
2,42 Hayarkon Street,Yavne,8122745,Israel,972 7 797 14100,972 7 797 14111,https://www.mediwound.com,Biotechnology,Healthcare,"MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.",83,"{'maxAge': 1, 'name': 'Dr. Ety  Klinger MBA, Ph.D.', 'age': 60, 'title': 'Chief R&D Officer', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 393000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,9.0,9.05,8.92,9.5,9.0,9.05,8.92,9.5,0.0,1.095781,-4.7395835,40748,40748,15720,42330,42330,8.03,9.55,800,800,86219408,7.1,14.58,3.3170242,9.0635,10.88194,0.0,0.0,USD,6122425,-0.55526,3789147,9474660,41079,46061,1690761600,1693440000,0.0043,0.24237,0.29609,3.88,0.0052,4.816,1.889535,1672444800,1703980800,1688083200,-14433000,-2.5,-1.92,-0.06,0.236,-0.75,NGM,EQUITY,MDWD,MDWD,MediWound Ltd.,MediWound Ltd.,1395322200,America/New_York,EDT,-14400000,9.1,36.0,23.0,27.25,25.0,1.7,buy,4,51122000,7.049,-8166000,677000,6.612,6.987,25993000,1.938,3.626,-0.12971,-0.88291,13165000,-7635750,-7165000,0.022,0.48301,-0.31416,-0.34120998,USD,
3,42 Hayarkon Street,Yavne,8122745,Israel,972 7 797 14100,972 7 797 14111,https://www.mediwound.com,Biotechnology,Healthcare,"MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.",83,"{'maxAge': 1, 'name': 'Ms. Hani  Luxenburg', 'title': 'Chief Financial Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,9.0,9.05,8.92,9.5,9.0,9.05,8.92,9.5,0.0,1.095781,-4.7395835,40748,40748,15720,42330,42330,8.03,9.55,800,800,86219408,7.1,14.58,3.3170242,9.0635,10.88194,0.0,0.0,USD,6122425,-0.55526,3789147,9474660,41079,46061,1690761600,1693440000,0.0043,0.24237,0.29609,3.88,0.0052,4.816,1.889535,1672444800,1703980800,1688083200,-14433000,-2.5,-1.92,-0.06,0.236,-0.75,NGM,EQUITY,MDWD,MDWD,MediWound Ltd.,MediWound Ltd.,1395322200,America/New_York,EDT,-14400000,9.1,36.0,23.0,27.25,25.0,1.7,buy,4,51122000,7.049,-8166000,677000,6.612,6.987,25993000,1.938,3.626,-0.12971,-0.88291,13165000,-7635750,-7165000,0.022,0.48301,-0.31416,-0.34120998,USD,
4,42 Hayarkon Street,Yavne,8122745,Israel,972 7 797 14100,972 7 797 14111,https://www.mediwound.com,Biotechnology,Healthcare,"MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.",83,"{'maxAge': 1, 'name': 'Mr. Tzvi  Palash B.Sc., M.Sc.', 'age': 65, 'title': 'Chief Operating Officer', 'yearBorn': 1957, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,9.0,9.05,8.92,9.5,9.0,9.05,8.92,9.5,0.0,1.095781,-4.7395835,40748,40748,15720,42330,42330,8.03,9.55,800,800,86219408,7.1,14.58,3.3170242,9.0635,10.88194,0.0,0.0,USD,6122425,-0.55526,3789147,9474660,41079,46061,1690761600,1693440000,0.0043,0.24237,0.29609,3.88,0.0052,4.816,1.889535,1672444800,1703980800,1688083200,-14433000,-2.5,-1.92,-0.06,0.236,-0.75,NGM,EQUITY,MDWD,MDWD,MediWound Ltd.,MediWound Ltd.,1395322200,America/New_York,EDT,-14400000,9.1,36.0,23.0,27.25,25.0,1.7,buy,4,51122000,7.049,-8166000,677000,6.612,6.987,25993000,1.938,3.626,-0.12971,-0.88291,13165000,-7635750,-7165000,0.022,0.48301,-0.31416,-0.34120998,USD,
5,42 Hayarkon Street,Yavne,8122745,Israel,972 7 797 14100,972 7 797 14111,https://www.mediwound.com,Biotechnology,Healthcare,"MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.",83,"{'maxAge': 1, 'name': 'Mr. Yaron  Meyer Adv.', 'age': 43, 'title': 'Exec. VP, Gen. Counsel & Corp. Sec.', 'yearBorn': 1979, 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,9.0,9.05,8.92,9.5,9.0,9.05,8.92,9.5,0.0,1.095781,-4.7395835,40748,40748,15720,42330,42330,8.03,9.55,800,800,86219408,7.1,14.58,3.3170242,9.0635,10.88194,0.0,0.0,USD,6122425,-0.55526,3789147,9474660,41079,46061,1690761600,1693440000,0.0043,0.24237,0.29609,3.88,0.0052,4.816,1.889535,1672444800,1703980800,1688083200,-14433000,-2.5,-1.92,-0.06,0.236,-0.75,NGM,EQUITY,MDWD,MDWD,MediWound Ltd.,MediWound Ltd.,1395322200,America/New_York,EDT,-14400000,9.1,36.0,23.0,27.25,25.0,1.7,buy,4,51122000,7.049,-8166000,677000,6.612,6.987,25993000,1.938,3.626,-0.12971,-0.88291,13165000,-7635750,-7165000,0.022,0.48301,-0.31416,-0.34120998,USD,
6,42 Hayarkon Street,Yavne,8122745,Israel,972 7 797 14100,972 7 797 14111,https://www.mediwound.com,Biotechnology,Healthcare,"MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.",83,"{'maxAge': 1, 'name': 'Mr. Barry J. Wolfenson', 'age': 55, 'title': 'Exec. VP of Strategy & Corp. Devel.', 'yearBorn': 1967, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,9.0,9.05,8.92,9.5,9.0,9.05,8.92,9.5,0.0,1.095781,-4.7395835,40748,40748,15720,42330,42330,8.03,9.55,800,800,86219408,7.1,14.58,3.3170242,9.0635,10.88194,0.0,0.0,USD,6122425,-0.55526,3789147,9474660,41079,46061,1690761600,1693440000,0.0043,0.24237,0.29609,3.88,0.0052,4.816,1.889535,1672444800,1703980800,1688083200,-14433000,-2.5,-1.92,-0.06,0.236,-0.75,NGM,EQUITY,MDWD,MDWD,MediWound Ltd.,MediWound Ltd.,1395322200,America/New_York,EDT,-14400000,9.1,36.0,23.0,27.25,25.0,1.7,buy,4,51122000,7.049,-8166000,677000,6.612,6.987,25993000,1.938,3.626,-0.12971,-0.88291,13165000,-7635750,-7165000,0.022,0.48301,-0.31416,-0.34120998,USD,
7,42 Hayarkon Street,Yavne,8122745,Israel,972 7 797 14100,972 7 797 14111,https://www.mediwound.com,Biotechnology,Healthcare,"MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.",83,"{'maxAge': 1, 'name': 'Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc.', 'age': 72, 'title': 'Chief Medical Officer', 'yearBorn': 1950, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,9.0,9.05,8.92,9.5,9.0,9.05,8.92,9.5,0.0,1.095781,-4.7395835,40748,40748,15720,42330,42330,8.03,9.55,800,800,86219408,7.1,14.58,3.3170242,9.0635,10.88194,0.0,0.0,USD,6122425,-0.55526,3789147,9474660,41079,46061,1690761600,1693440000,0.0043,0.24237,0.29609,3.88,0.0052,4.816,1.889535,1672444800,1703980800,1688083200,-14433000,-2.5,-1.92,-0.06,0.236,-0.75,NGM,EQUITY,MDWD,MDWD,MediWound Ltd.,MediWound Ltd.,1395322200,America/New_York,EDT,-14400000,9.1,36.0,23.0,27.25,25.0,1.7,buy,4,51122000,7.049,-8166000,677000,6.612,6.987,25993000,1.938,3.626,-0.12971,-0.88291,13165000,-7635750,-7165000,0.022,0.48301,-0.31416,-0.34120998,USD,
